Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005
(RTTNews) - Cadrenal Therapeutics (CVKD) presented late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005. The Phase 2 Data demonstrated greater than 25% reduction in Thrombotic events in Heparin-Induced Thrombocytopenia for CAD-1005.
Quang Pham, CEO of Cadrenal Therapeutics said: "With our recent financing, we are well-positioned to advance partnering opportunities for CAD-1005 and tecarfarin."
CAD-1005 has received Orphan Drug and Fast Track designations from the FDA and Orphan Drug status from the European Medicines Agency.
Cadrenal Therapeutics shares are currently down 7.27 percent to $2.68.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.